Search results
Showing 106 to 120 of 496 results for 2011
NICE has developed a medtech innovation briefing (MIB) on RT300 for spinal cord injury rehabilitation .
The OraQuick HCV point‑of‑care test for rapid detection of hepatitis C virus antibodies (MIB24)
NICE has developed a medtech innovation briefing (MIB) on the OraQuick HCV point-of-care test for rapid detection of hepatitis C virus antibodies
Evidence-based recommendations on PeritX for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites.
Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver.
NICE has developed a medtech innovation briefing (MIB) on End-tidal Control software for use with Aisys closed circuit anaesthesia systems for automated gas control during general anaesthesia .
Evidence-based recommendations on SecurAcath for securing percutaneous catheters.
NICE has developed a Medtech Innovation Briefing (MIB) on the AccuVein AV400 for vein visualisation
Xpert GBS test for the intrapartum detection of group B streptococcus (MIB28)
NICE has developed a medtech innovation briefing (MIB) on Xpert GBS test for the intrapartum detection of group B streptococcus
Biomarker tests to help diagnose preterm labour in women with intact membranes (HTG476)
Evidence-based recommendations on biomarker tests to help diagnose preterm labour in women with intact membranes. The tests are Actim Partus, PartoSure and the Rapid fetal fibronectin (fFN) 10Q Cassette Kit (at thresholds other than 50 nanograms/millilitre).
PredictSURE IBD for inflammatory bowel disease prognosis: ulcerative colitis (MIB313)
NICE has developed a medtech innovation briefing (MIB) on PredictSURE IBD for inflammatory bowel disease prognosis: ulcerative colitis .
This guideline covers diagnosing and managing rheumatoid arthritis. It aims to improve quality of life by ensuring that people with rheumatoid arthritis have the right treatment to slow the progression of their condition and control their symptoms. People should also have rapid access to specialist care if their condition suddenly worsens.
Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults after 2 or more anti-HER2 therapies.
NICE's guidance executive is made up of executive directors, guidance centre directors and senior team members.
NICE has developed a Medtech Innovation Briefing (MIB) on the SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional
Sternal Talon for sternal closure in cardiothoracic surgery (MIB88)
NICE has developed a medtech innovation briefing (MIB) on the Sternal Talon for sternal closure in cardiothoracic surgery .